Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure  by Vaziri, Nosratola D. et al.
Kidney International, Vol. 59 (2001), pp. 2192–2196
Down-regulation of hepatic lecithin:cholesterol acyltransferase
gene expression in chronic renal failure
NOSRATOLA D. VAZIRI, KAIHUI LIANG, and JOHN S. PARKS
Division of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California, and
Department of Pathology, Section of Comparative Medicine, Wake Forest University, Winston-Salem, North Carolina, USA
Down-regulation of hepatic lecithin:cholesterol acyltransferase Chronic renal failure (CRF) is associated with in-
gene expression in chronic renal failure. creased risk of arteriosclerotic cardiovascular disease
Background. Chronic renal failure (CRF) is associated with and profound abnormalities of lipid metabolism [1]. Thepremature arteriosclerosis, impaired high-density lipoprotein
reported CRF-induced lipid abnormalities include hy-(HDL) maturation, increased pre-b HDL (a lipid-poor HDL
pertriglyceridemia, elevated plasma very low-density lipo-species), reduced HDL/total cholesterol ratio, hypertriglyceri-
demia, and depressed lipolytic activity. The latter has been, protein (VLDL), apolipoprotein B (apoB), pre-b high-
in part, attributed to elevated pre-b HDL, which is a potent density lipoprotein (HDL), and lipoprotein (a), coupled
inhibitor of lipoprotein lipase (LPL). Accumulation of choles- with diminished plasma apoA-1 and HDL cholesterolterol in the arterial wall is a critical step in atherogenesis, and
concentrations [2–5]. This is associated with triglycerideHDL-mediated cholesterol removal from peripheral tissues
enrichment and impaired clearance of VLDL and chy-mitigates atherosclerosis. Lecithin:cholesterol acyltransferase
(LCAT) is essential for maturation of HDL and cholesterol lomicrons and elevated plasma concentrations of VLDL
removal by HDL from peripheral tissues. Earlier studies have and chylomicron remnants [2, 6, 7]. The latter abnormali-
revealed depressed plasma LCAT enzymatic activity in patients ties are largely due to CRF-induced down-regulation ofwith CRF. This study was conducted to determine whether
lipoprotein lipase (LPL), hepatic triglyceride lipase, andimpaired LCAT activity can be confirmed in CRF animals and
VLDL receptor expression [8–11] coupled with eleva-if so whether it is due to down-regulation of hepatic LCAT
expression. tions of plasma, apoC-III, and pre-b HDL, which are
Methods. Hepatic tissue LCAT mRNA and plasma LCAT potent inhibitors of LPL [12].
enzymatic activity were measured in male Sprague-Dawley rats Plasma total cholesterol is frequently low to normalsix weeks after excisional 5/6 nephrectomy or sham operation.
and only occasionally elevated in CRF patients. In addi-Results. Compared with the controls, the CRF group exhib-
tion, HMG CoA reductase, the rate-limiting step in cho-ited a significant reduction of hepatic tissue LCAT mRNA
abundance. The reduction in hepatic LCAT mRNA was ac- lesterol biosynthesis, and cholesterol 7a-hydroxylase, the
companied by a marked reduction of plasma LCAT activity rate-limiting step in cholesterol catabolism, are unaf-
and elevation of serum-free cholesterol in the CRF animals. fected by CRF [13]. Moreover, LDL receptor and scav-LCAT activity correlated positively with the HDL/total choles-
enger receptor BI, the primary pathways of hepatic cho-terol ratio and inversely with free cholesterol and triglyceride
lesterol uptake, are normal in CRF [14]. However, HDLconcentrations.
Conclusions. CRF leads to a marked down-regulation of maturation is impaired. The plasma HDL cholesterol-
hepatic LCAT mRNA expression and plasma LCAT activity. to-total cholesterol ratio is markedly reduced [2], and
This abnormality can impair HDL-mediated cholesterol up- pre-b HDL, which is a lipid-poor HDL species, is ele-take from the vascular tissue and contribute to cardiovascular
vated in CRF [12].disease. In addition, LCAT deficiency can, in part, account for
Lecithin:cholesterol acyltransferase (LCAT) is a 63 toelevated serum-free cholesterol, reduced HDL/total choles-
terol, and elevated pre-b HDL in CRF. The latter can, in turn, 65 kD plasma glycoprotein that is responsible for the
depress lipolytic activity and hinder triglyceride-rich lipopro- synthesis of most cholesteryl esters (CEs) found in
tein clearance in CRF. plasma [15]. The enzyme catalyzes the hydrolysis of a
sn-2 fatty acid from phospholipid and the transesterifica-
tion of the fatty acid to the 3-hydroxyl group of choles-Key words: high-density lipoprotein, LCAT, lipid disorder, arterioscle-
rosis, cardiovascular disease, hypertriglyceridemia. terol to form CE and lysophospholipid [15]. ApoA-I
serves as a cofactor for the reaction and is the majorReceived for publication July 7, 2000
structural apolipoprotein of HDLs, which are the pre-and in revised form December 1, 2000
Accepted for publication January 8, 2001 ferred macromolecular substrate particle for the LCAT
reaction [16–18]. LCAT is essential for maturation ofÓ 2001 by the International Society of Nephrology
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HDLs that are secreted from the liver and intestine or rum cholesterol, triglyceride, and creatinine concentra-
tions and urinary protein and creatinine contents wereformed during lipolysis of triglyceride-rich lipoproteins
[19]. The generation of CE by LCAT converts nascent determined as described previously [13]. Arterial blood
pressure was determined by a tail sphygmomanometerdiscoidal HDL to spherical particles, which are the pre-
dominant form of HDL in plasma. The importance of (Harvard Apparatus, South Natick, MA, USA).
LCAT in the HDL maturation process is best illustrated
RNA preparation and Northern blot analysisby genetic [20] or induced [21] LCAT deficiency states
in which nascent discoidal HDL accumulate in plasma Total RNA was prepared from 0.2 g of frozen liver
tissue with RNAzol using the manufacturer’s recom-and CE concentrations are very low. LCAT is also
thought to play an important role in reverse cholesterol mended procedure (Tel-Test Inc., Friendswood, TX,
USA). RNA concentration was determined from thetransport, the process by which excess free cholesterol
is removed from peripheral tissues by HDL and trans- absorbance at 260 nm using a spectrophotometer (Gene-
Quat; Bio-Rad, Hercules, CA, USA). Twenty-five micro-ported to the liver for excretion [15]. The role of LCAT
in this process appears to be the generation of a chemical gram aliquots of total RNA were denatured in 2.2 mol/L
formaldehyde at 658C for 15 minutes and run on 1%gradient for the flux of free cholesterol from cells into
HDL by decreasing the concentration of free cholesterol agarose/2.2 mol/L formaldehyde gel at 40 V for five
hours. The separated RNA was transferred to the nylonin HDL through its conversion to CE.
Earlier studies have shown a reduction in plasma membrane (Zeta probe; Bio-Rad) by capillary blotting
in 6 3 standard saline citrate (SSC) buffer (0.9 mol/LLCAT enzymatic activity in dialysis-dependent patients
with end-stage renal disease [22]. Given the central role NaCl, 0.09 mol/L Na citrate, pH 7.0) overnight and im-
mobilized by ultraviolet irradiation (Ultraviolet Cros-of LCAT in reverse cholesterol transport by HDL, its
deficiency can account for low HDL cholesterol concen- slinker; Fisher Scientific, Pittsburgh, PA, USA). The
membrane was incubated at 658C in a solution containingtration and increased pre-b HDL in CRF. The present
study was designed to determine whether the reported 5 3 SSPE [0.75 mol/L NaCl, 0.05 mol/L NaH2PO4,
0.005 mol/L ethylenediaminetetraacetic acid (EDTA),impairment of plasma LCAT activity in patients can be
confirmed in CRF animals and, if so, whether it is due pH 7.4], 5 3 Denhard’s [Ficoll (type 400), polyvinylpyr-
rolidone, bovine serum albumin (fraction 5) 1 g/L each],to depressed LCAT gene expression.
1% sodium dodecyl sulfate (SDS), and 100 mg/mL
salmon sperm DNA for two hours. The cDNA probes
METHODS
for rat LCAT (1.35 kb EcoR I and HindII fragment of
Animal models R1P1) were supplied by Professor John S. Parks (Wake
Forest University School of Medicine, Winston-Salem,Male Sprague-Dawley rats weighing 225 to 250 g were
purchased from Harlan Sprague Dawley Inc. (Indianap- NC, USA), and rat glyceraldehyde phosphate dehydro-
genase (GAPDH; 1.3 kb Pst I fragment) was obtainedolis, IN, USA). They were housed in a climate-con-
trolled, light-regulated facility with 12-hour day (,500 from American Type Culture Collection (Rockville,
MD, USA). Both probes were labeled with [32P] dCTPlux) and 12-hour night (,5 lux) cycles. The animals were
fed regular rat chow (Purina Mills, Brentwood, MO, (3000 Ci/mmol; New England Nuclear Inc., Boston, MA,
USA) by the random primer method (Promega Inc.,USA) and water ad libitum. They were then randomly
assigned to the following groups. A minimum of six ani- Madison, WI, USA). Hybridization was carried out at
658C in a prehybridization solution with 32P-labeledmals was used in each group.
(1) The CRF group. Animals assigned to the CRF cDNA. The blots were washed twice in 2 3 SSPE/0.5%
SDS solution at room temperature, twice in 1 3 SSPE/group were subjected to 5/6 nephrectomy by surgical re-
section using a dorsal incision as described previously [9]. 0.5% SDS solution at 378C, and twice in 0.1 3 SSPE/
0.5% SDS solution at 658C for 15 minutes each. The(2) The control group. The animals assigned to the
control group were subjected to sham operation and washed blots were exposed to x-ray film (New England
Nuclear Inc.) at 2808C for six hours for GAPDH andwere provided free access to food and water.
The study groups were observed for five weeks, at two days for LCAT. The autoradiographs were scanned
with a laser densitometer (Molecular Dynamics, Sun-which point they were placed in metabolic cages for
a 24-hour urine collection. They were then sacrificed nyvale, CA, USA) to determine relative mRNA levels.
The values obtained for GAPDH were used as thebetween the hours of 9 and 11 a.m. by exsanguination
using cardiac puncture. The liver was removed immedi- internal control.
ately, snap frozen in liquid nitrogen, and stored at 2708C
LCAT activity assayuntil processed. All surgical procedures were carried out
under general anesthesia (Nembutal, 50 mg/kg, IP) while Lecithin:cholesterol acyltransferase incubations were
performed in duplicate using an exogenous substrateobserving strict hemostasis and aseptic techniques. Se-
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Table 1. Creatinine clearance (CCr), serum concentrations of creatinine, triglycerides, total cholesterol, free cholesterol, LDL, HDL, and
VLDL, HDL cholesterol-to-total cholesterol (HDL-C/TC) ratio, urinary protein excretion, systolic arterial pressure and body weight
in chronic renal failure (CRF) and sham-operated control (CTL) groups
Control (N56) CRF (N56) P values
Creatinine clearance mL/min 1.8260.15 0.4860.05 ,0.001
Serum creatinine mg/mL 0.660.06 1.6260.12 ,0.001
Serum triglycerides mg/mL 43.561.6 108.669.3 ,0.001
Serum cholesterol mg/dL 73.562.4 163.869.6 ,0.001
Serum LDL-chol mg/dL 3761.7 9168.8 ,0.001
Serum HDL-chol mg/dL 28.561.2 33.2653 NS
Serum free cholesterol 23.761.4 50.566.0 ,0.001
Serum VLDL-chol mg/mL 7.761.2 30.265.2 ,0.001
HDL-C/TC (ratio) 0.3860.01 0.2660.01 ,0.005
Urine protein mg/24 h 8.360.7 33.664.0 ,0.001
Blood pressure mm Hg 10866 147611 ,0.005
Body weight g 44267.8 40965.9 ,0.05
Abbreviations are: LDL, low-density lipoprotein; HDL, high-density lipoprotein; VLDL, very low-density lipoprotein.
assay as described previously [23, 24]. The exogenous group showed a significant increase in plasma triglycer-
substrate consisted of recombinant HDL (rHDL) parti- ide, total cholesterol, free cholesterol, LDL cholesterol,
cles containing sn-1 16:0, sn-2 20:4 phosphatidylcholine, and VLDL cholesterol concentrations. However, despite
3H-cholesterol, and human apoA-I, made by cholate dial- significant elevations of total cholesterol concentrations,
ysis [23]. Assays of initial reaction velocity were per- plasma HDL cholesterol was unchanged, and the plasma
formed in 0.5 mL buffer (10 mmol/L Tris, 140 mmol/L HDL cholesterol-to-total cholesterol concentration ratio
NaCl, 0.01% EDTA, 0.01% NaN3, pH 7.4) containing was markedly reduced in the CRF group as compared
rHDL (1.2 mg cholesterol; saturating substrate concen- with the corresponding values found in the control group.
tration), 0.6% bovine serum albumin (fatty acid-free; Compared with the control group, the CRF animals ex-
Sigma Chemical Co., St. Louis, MO, USA), 2 mmol/L hibited a significant rise in arterial blood pressure.
b-mercaptoethanol, and 5 mL rat plasma as a source of
LCAT dataLCAT. Incubations were performed for 15 minutes, after
which the free and esterified cholesterol radiolabel was Hepatic tissue LCAT mRNA abundance was signifi-
extracted and quantitated [25]. cantly lower in the CRF group as compared with that
found in the sham-operated controls (Fig. 1). The reduc-
Miscellaneous assays tion in hepatic tissue LCAT mRNA was accompanied
A colorimetric assay was used to measure serum and by a parallel fall in plasma LCAT activity in the CRF
urine creatinine concentrations using a kit obtained from group (Fig. 2). These observations point to acquired
Sigma Chemical Co. Plasma concentrations of total cho- down-regulation of LCAT in rats with CRF. Plasma
lesterol and free cholesterol were measured by enzymatic LCAT activity was directly related to hepatic LCAT
colorimetric assays using kits supplied by Wako Chemi- mRNA abundance (r 5 0.87, P , 0.001) pointing to
cal Company (Richmond, VA, USA). Plasma HDL and transcriptional regulation of LCAT in the study animals.
LDL cholesterol concentrations and triglyceride level were Plasma LCAT activity was directly related to the HDL/
determined by kits purchased from Sigma Chemical Co. total cholesterol ratio (r 5 0.84, P , 0.005) and inversely
to the plasma triglyceride concentration (r 5 20.81, P ,
Data analysis 0.005) and plasma-free cholesterol concentration (r 5
Student t test and regression analysis were performed 20.78, P , 0.05).
in statistical analysis of the data that are presented as
mean 6 SEM. P values less than 0.05 were considered
DISCUSSIONsignificant.
The CRF animals employed in the present study ex-
hibited a marked reduction of plasma LCAT enzymatic
RESULTS activity. The reduction in plasma LCAT activity in our
General data CRF rats is consistent with an earlier report by Bories,
Subbaiah, and Bagdade, who showed depressed plasmaAs shown in Table 1, the CRF group exhibited a sig-
LCAT enzymatic activity in patients with end-stage renalnificant increase in plasma creatinine concentration and
disease [22]. The reduction in plasma LCAT enzymatica significant reduction in creatinine clearance as com-
pared with the sham-operated control group. The CRF activity using an exogenous substrate assay in our CRF
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Fig. 1. (A) Representative Northern blot of hepatic lecithin:cholesterol
acyltransferase (LCAT) and glyceraldehyde phosphate dehydrogenase
Fig. 2. Plasma LCAT enzymatic activity (A) and plasma-free choles-(GAPDH) mRNA in three animals with chronic renal failure (CRF)
terol concentration (B) in six rats with chronic renal failure (CRF) andand three sham-operated normal control (NL) rats. (B) Group data
six normal control (NL) animals. *P , 0.001.depicting the hepatic LCAT/GAPDH mRNA ratio in the study groups.
N 5 6 animals in each group. *P , 0.01.
tion of hepatic LCAT production in CRF. In fact, the
animals was accompanied by a significant reduction in CRF-associated inflammation has been implicated in the
hepatic tissue LCAT mRNA abundance when compared pathogenesis of impaired biosynthesis of albumin and
with the control group. This observation suggests that transferrin, which like LCAT, are produced and secreted
impaired plasma LCAT activity reported in CRF pa- by the liver [26].
tients previously [22] and shown in CRF rats in our As noted in the introduction, LCAT plays a critical
current study must be due to quantitative deficiency of role in the HDL-mediated cholesterol uptake from the
the enzyme as opposed to its inhibition by the uremic peripheral tissues. Thus, LCAT deficiency can, at least
milieu. Accordingly, these data suggest that experimen- in part, account for the reduction of plasma HDL choles-
tal CRF leads to an acquired down-regulation of hepatic terol-to-total cholesterol ratio known to occur in CRF
LCAT gene expression in the rat. [2] and exemplified by CRF animals employed in this
The available data do not allow definitive conclusions study. Similarly, LCAT deficiency can contribute to the
as to the mechanism(s) by which CRF leads to down- reported elevation of pre-b HDL, which is a lipid-free
regulation of hepatic LCAT gene expression. Little is HDL species, in CRF [12]. It is of interest that pre-b
known about LCAT metabolism and regulation in health HDL has been recently shown to be a potent inhibitor
and disease. LCAT appears to be constitutively secreted of LPL. Elevation of pre-b HDL is thought to contribute
by the liver, and very few perturbations are known to to impaired lipolytic activity and depressed clearance of
affect LCAT biosynthesis except for inflammatory medi- triglyceride-rich lipoproteins in CRF [12]. Accordingly,
ators which depress LCAT production [21, 26]. Interest- the CRF-induced LCAT deficiency may indirectly im-
ingly, inflammation has been shown to be a common pact triglyceride metabolism via elevation of pre-b HDL
feature of CRF [27]. Therefore, the associated inflam- and the resultant inhibition of lipolytic pathway. More-
over, in humans who unlike rats possess cholesterol estermatory state can potentially contribute to down-regula-
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lipase in chronic renal failure: Role of excess parathyroid hormone.transfer protein (CETP), the reduction in cholesterol
J Clin Invest 97:2167–2173, 1996
ester content of HDL can possibly limit the triglyceride 11. Vaziri ND, Liang K: Down-regulation of VLDL receptor expres-
sion in chronic experimental renal failure. Kidney Int 51:913–919,for CE exchange between VLDL and HDL in the circu-
1997lation. This can contribute further to triglyceride enrich-
12. Cheung AK, Parker CJ, Ren K, et al: Increased lipase inhibition
ment of VLDL particles and their remnants in CRF [2]. in uremia: Identification of pre-beta-HDL as a major inhibitor in
normal and uremic plasma. Kidney Int 49:1360–1371, 1996In conclusion, CRF results in marked down-regulation
13. Liang K, Vaziri ND: Gene expression of LDL receptor, HMG-of LCAT expression and activity. Acquired LCAT defi-
CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic
ciency can depress cholesterol uptake from peripheral tis- renal failure. Nephrol Dial Transplant 12:1381–1386, 1997
14. Vaziri ND, Deng G, Liang K: Hepatic HDL receptor, SR-B1sues by HDL and contribute to accumulation of choles-
and Apo A-I expression in chronic renal failure. Nephrol Dialterol in the vascular tissue and atherosclerosis in CRF.
Transplant 14:1462–1466, 1999
Moreover, reduced cholesterol uptake can, in part, account 15. Glomset JA: The plasma lecithins:cholesterol acyltransferase reac-
tion. J Lipid Res 9:155–167, 1968for CRF-induced abnormalities of plasma lipid profile.
16. Fielding CJ, Shore VG, Fielding PE: A protein cofactor of leci-
thin:cholesterol acyltransferase. Biochem Biophys Res Commun
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